Document Detail

De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group.
MedLine Citation:
PMID:  7532766     Owner:  NLM     Status:  MEDLINE    
A 4-year prospective study of de novo acute myeloid leukaemia in patients aged 56 years and over was undertaken in the Northern Region of England (population 3.09 million). The study was conducted to assess the incidence and outcome of treatment in all elderly patients diagnosed between January 1, 1988 and December 31, 1991. Two hundred cases de novo AML were confirmed, giving an incidence of 6.05/10(5) per annum (age specific population) (95% Cl, 5.2-6.9). Acute promyelocytic leukaemia was rare. Erythroleukaemia, monocytic leukaemia and AML with trilineage myelodysplasia were more common than in younger patients. Karyotypic abnormalities classically associated with response to therapy were present in only six of 91 patients where cytogenetic data was available. Treatment was at the discretion of the physician in charge: if given, specific treatment was recorded and clinical outcome assessed. Only 84 (42%) of patients received treatment with curative intent. Forty-four of 84 achieved a complete remission, usually of brief duration. A normal karyotype in leukaemic cells was associated with a survival advantage in this group (p < 0.05). Actuarial overall survival at 4 years for the entire group was 2.5%. Even with aggressive treatment, the outcome is poor. The pattern of disease and its lack of response to conventional treatment would support the hypothesis that AML in the elderly may differ biologically from that observed in younger patients. Karyotyping appears to predict those patients likely to benefit from intensive therapy and decisions about management in otherwise fit patients should, if possible, be delayed until a result is obtained. Every effort should be made to give such patients optimal treatment. However, most patients are unsuitable for aggressive treatment and, since long-term survival is rare, cure should not be offered as an inducement to accept such treatment and improving quality of life outside hospital should be the aim of treatment in this group.
P R Taylor; M M Reid; A N Stark; N Bown; P J Hamilton; S J Proctor
Related Documents :
18324966 - Therapy-associated genetic aberrations in patients treated for non-hodgkin lymphoma.
1794966 - Update on the prognostic implication of morphology, histology, and karyotype in primary...
17051246 - High efficacy and safety profile of fractionated doses of mylotarg as induction therapy...
19344426 - Prognostic factor analysis of the survival of elderly patients with aml in the mrc aml1...
9063376 - Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopo...
17033326 - Esophageal carcinoma: surgery, radiotherapy, and chemotherapy.
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Leukemia     Volume:  9     ISSN:  0887-6924     ISO Abbreviation:  Leukemia     Publication Date:  1995 Feb 
Date Detail:
Created Date:  1995-03-30     Completed Date:  1995-03-30     Revised Date:  2013-03-04    
Medline Journal Info:
Nlm Unique ID:  8704895     Medline TA:  Leukemia     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  231-7     Citation Subset:  IM    
Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Marrow Transplantation
England / epidemiology
Leukemia, Myeloid / classification,  epidemiology*,  genetics,  therapy
Middle Aged
Palliative Care
Prospective Studies
Remission Induction
Survival Analysis
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  On the origin of protein synthesis: a speculative model based on hairpin RNA structures.
Next Document:  CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leu...